Alexion Pharmaceuticals introduces Ultomiris SC, unveiling a third option for home infusion, providing patients with atypical hemolytic uremic syndrome (aHUS) the convenience of self-administering the drug in their own homes. This comprehensive campaign encompasses a user-friendly website, instructional videos guiding patients through the administration process, and visually appealing brochures designed to assist doctors in effectively informing their patients. With a focus on accessibility and patient empowerment, Ultomiris SC marks a significant advancement in aHUS treatment options, offering greater flexibility and convenience for those managing this challenging condition.